SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ray Tarke who wrote (900)5/23/1998 12:48:00 AM
From: Jeffrey L. Henken  Read Replies (1) of 2887
 
Yesterday's press release did not adequately address the full market potential of the OmniCath atherectomy device.

Why is that?

At this point in time clinical trials for the peripheral vascular market are the only application approved by the FDA for the OmniCath.

But American BioMed has other markets in mind as well. Our company has filed a 510 with the FDA which will allow testing for the AV Fistula market. I think that the FDA will rule favorably that the current phase II trials being set up by the company will satisfy FDA requirements that will help speed the OmniCath through AV Fistula trials and rapid approval.

What about coronary indications?

The OmniCath in my opinion will eventually be the premiere atherectomy device used in any and all of these markets.

Would you like to run the numbers for the OmniCath in all these markets with me?

The peripheral vascular market- $100 Million a year

The AV Fistula Market-          $156 Million a year

The coronary market-            $250 Million a year


Total markets exceed $500 million a year in the US alone!

So what is an AV Fistula?

In lay terms the AV Fistula in removal of plaque/restenosis from an open access or graft placement in a peripheral artery.

This is a very common problem that needs a solution like the OmniCath.

Presently, the only way to do this to use balloon angioplasty and it does not work. Every 90 days the doctor must go back in and do another balloon angioplasty procedure and in 12 - 15 months a revision or new graft must be put in because the artery is so weakened from all the angioplasty procedures.

With the OmniCath the doctor goes in 90 days after the graft is initially placed and removes the restenosis or lesion that has formed and then the next procedure will not have to take place for between 270 - 450 days. This results in a significant cost savings to the medical system and a lot less trauma to the patient.

The OmniCath could be approved for AV fistula indications in as little as 12 months after the FDA approves the 510. American BioMed is currently waiting for the 510 approval.

It could happen anytime now!

GO ABMI!

Regards, Jeff
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News